Cdc42 regulates cell polarization and contractile actomyosin rings during terminal differentiation of human erythroblasts

Kumi Ubukawa1,5, Tatsufumi Goto2,5, Ken Asanuma3, Yumi Sasaki2, Yong-Mei Guo1, Isuzu Kobayashi1, Kenichi Sawada4, Hideki Wakui2 & Naoto Takahashi1

The molecular mechanisms involved in the terminal differentiation of erythroblasts have been elucidated by comparing enucleation and cell division. Although various similarities and differences between erythroblast enucleation and cytokinesis have been reported, the mechanisms that control enucleation remain unclear. We previously reported that dynein and microtubule-organizing centers mediated the polarization of nuclei in human erythroblasts. Moreover, the accumulation of F-actin was noted during the enucleation of erythroblasts. Therefore, during enucleation, upstream effectors in the signal transduction pathway regulating dynein or actin, such as cell division control protein 42 homolog (Cdc42), may be crucial. We herein investigated the effects of the Cdc42 inhibitor, CASIN, on cytokinesis and enucleation in colony-forming units-erythroid (CFU-Es) and mature erythroblasts (day 10). CASIN blocked the proliferation of CFU-Es and their enucleation in a dose-dependent manner. Dynein adopted an island-like distribution in the cytoplasm of non-treated CFU-Es, but was concentrated near the nucleus as a dot and co-localized with γ-tubulin in CASIN-treated cells. CASIN blocked the accumulation of F-actin in CFU-Es and day 10 cells. These results demonstrated that Cdc42 plays an important role in cytokinesis, nuclear polarization and nuclear extrusion through a relationship with dynein and actin filament organization during the terminal differentiation of erythroblasts.
filaments during the terminal differentiation of human erythroblasts, are regulated by either one or multiple signal transduction pathway(s).

The structure of F-actin at the rear of the translocating nucleus, which is essential for the extrusion of the nucleus, differs between enucleation and cytokinesis. The F-actin structure in erythroblasts is enriched with tropomodulin 1 and non-muscle myosin IIB and extrudes the nucleus. Wolfer et al. previously reported that nuclear extrusion required intracellular calcium signal transduction through the calmodulin and myosin light chain kinase pathway, similar to cytokinesis. However, erythroblasts required extracellular calcium uptake for enucleation, in contrast to cytokinesis. Erythroblast enucleation and asymmetric cell division were also compared. Asymmetric cell division regulators were not required for erythroblast enucleation. In addition, histone deacetylases, proteosomal regulators, mitogen-activated protein kinases, and cyclin-dependent kinases were identified as molecules involved in erythroblast enucleation using a novel chemical screening approach. Although F-actin and non-muscle myosin IIB are involved in the enucleation of erythroblasts, enucleation and cytokinesis are not the same phenomenon.

Cell division control protein 42 homolog (Cdc42) is a member of the Ras homolog (Rho) guanosine triphosphatase (GTPase) family of the Ras superfamily, and, in response to various extracellular stimuli, functions as a binary molecular switch that cycles between guanosine triphosphate (GTP)- and guanosine diphosphate (GDP)-bound active states. Cdc42 regulates the formation of the actin cytoskeleton and microtubule assembly through several effector proteins, such as the IQ motif-containing GTPase-activating protein (IQGAP), p21-activated kinase (PAK), possibly the partitioning-defective (Par)3/Par6 complex, and Wiskott-Aldrich syndrome protein homolog (WASP)/neural-WASP (N-WASP). These regulators function in cell polarization, division, and movement. Toyoshima et al. and Mitsushima et al. also demonstrated that the activation of F33k by Cdc42 required the accumulation of dynactin, a dynein-binding molecule, for cell polarization in HeLa cells. Collectively, these findings indicate that upstream effectors in the signal transduction pathway regulating dynemin, such as the small GTPase Cdc42, are crucial during the terminal differentiation of human erythroblasts.

mDia2, a member of the mDia family, is the main functional effector molecule and is regulated by Cdc42 in somatic cells. Watanabe et al. has shown that mDia2 is essential in mammalian cell cytokinesis and that mDia2-induced F-actin forms a scaffold for the contractile ring and then maintains its position in the center of dividing cells. Furthermore, Yi et al. showed that mDia2 plays a significant role in enucleation by affecting the formation of the contractile actomyosin ring in mouse erythroblasts. These findings indicate that Cdc42 regulates the enucleation of human erythroblasts mediated by mDia2. However, Watanabe et al. reported that mDia2-deficient erythroblasts may be enucleated.

Although the basic strategy for a functional analysis of target molecules is the knockdown of the gene expression of target molecules, difficulties are associated with transforming interfering small RNA (siRNA) and/or some expression vectors into primary culture cells, such as erythroblasts. Specific inhibitors are generally used in studies on the functions of target molecules. A highly specific inhibitor of Cdc42 activity-specific inhibitor, CASIN, was previously shown to be decreased in human erythroblasts during terminal differentiation.

**Results**

**Expression of Cdc42 in human CFU-Es and erythroblasts during terminal differentiation.** We examined Cdc42 expression in human CFU-Es and erythroblasts. Regarding protein levels, the immunoblot analysis clearly showed that Cdc42 was constantly expressed in human CFU-Es and erythroblasts, and that the normalized protein levels of Cdc42 increased in erythroblasts during terminal differentiation (Fig. 1A). The expression of α-tubulin, used as a standard for normalization, decreased during terminal differentiation (Fig. 1A). Erythroblasts become smaller as they differentiate and have less protein overall for the same number of cells. We also examined GAPDH as the standard for normalization; however, the results obtained were similar to α-tubulin (data not shown). Original immunoblots were shown in SI Fig. S1. The real-time PCR analysis showed that Cdc42 relative mRNA levels remained unchanged until day 11. On day 13, Cdc42 relative mRNA levels increased (Fig. 1B).

**CASIN inhibited the proliferation and differentiation of human CFU-Es.** We investigated the effects of the inhibition of Cdc42 on the proliferation and differentiation of human CFU-Es. The proliferation of CFU-Es was reduced by the CASIN treatment in a concentration-dependent manner (Fig. 2A). The proliferation of erythroblasts was completely inhibited by 25 μM of CASIN, whereas that of DMSO-treated cells as the control was not. The gene and protein expression levels of Cdc42 were not significantly altered in cells cultured with or without CASIN for 48 h (data not shown). We then assessed the effects of CASIN on cell cycle patterns in CFU-Es. After incubating cells for an additional 24 h with CASIN, the cell cycle analysis showed that CASIN reduced the cell fraction in the G2/M phase to significantly less than that with DMSO (9.5 ± 0.6%, 12.7 ± 1.6%, respectively) (Fig. 2B). CASIN-treated cells were larger than control cells at 48 h (Fig. 2C). In the FACS analysis using antibodies to CD71 (transferrin receptor) and GPA, the ratio of cells that expressed these erythroid-specific markers was not altered by the CASIN treatment. CASIN-treated cells were observed to have a cell population accumulated in the upper right as compared with DMSO-treated cells (Fig. 2D). CD71 expression levels were previously shown to be decreased in human erythroblasts during terminal differentiation. Interestingly, the expression of CD71 decreased in DMSO-treated cells, but not in CASIN-treated cells, which was similar to the expression of CD71 in cells at 0 h (Fig. 2E). These results showed that the inhibition of Cdc42 by CASIN blocked the proliferation and differentiation of CFU-Es.
CASIN inhibited the enucleation of human erythroblasts. We examined the effects of the inhibition of Cdc42 on the enucleation of erythroblasts. The ratio of enucleation of erythroblasts was reduced by the CASIN treatment in a concentration-dependent manner (Fig. 3A). We then assessed the effects of CASIN on cell cycle patterns in erythroblasts during terminal differentiation. After incubating cells for an additional 24 h with CASIN, the cell cycle analysis showed that none of the phases were altered in the presence of CASIN (Fig. 3B). The enucleation of human erythroblasts was completely inhibited by 25 μM of CASIN, whereas that of DMSO-treated cells was not (Fig. 3C). The gene and protein expression levels of Cdc42 were not significantly changed in cells cultured with or without CASIN for 48 h (data not shown).

In the FACS analysis using antibodies to CD71 and GPA, the ratio of cells that expressed these erythroid specific markers was not changed by the CASIN treatment (Fig. 3D). Additionally, the expression of CD71 was decreased in both DMSO- and CASIN-treated cells (Fig. 3E). These results showed that the inhibition of Cdc42 by CASIN blocked the enucleation, but not differentiation, of erythroblasts from day 10.

We then investigated the effects of CASIN on the positioning of the nucleus in erythroblasts undergoing terminal differentiation. After incubating day 10 cells for an additional 24 h with CASIN, the ratio of centered, polarized, and others significantly increased over that in DMSO-treated cells. In contrast, the ratio of reticulocytes in CASIN-treated cells was lower than that in DMSO-treated cells (Fig. 4). This result showed that the inhibition of Cdc42 by CASIN blocked the polarization and extrusion of nuclei in human erythroblasts during terminal differentiation.

Effects of inhibiting Cdc42 by CASIN on the localization of Cdc42, mDia2, and actin filaments in human CFU-Es and erythroblasts during terminal differentiation. In CFU-Es (day 8 cells), Cdc42 was localized beside the contractile actomyosin ring (Fig. 5A). However, in cells incubated with CASIN for an additional 24 h, Cdc42 was not localized in the specific contractile actomyosin ring point and, thus, this ring was not formed (Fig. 5A). In day 11 cells, Cdc42 was localized beside the accumulation of F-actin, similar to CFU-Es (Fig. 5B). Furthermore, after enucleation, Cdc42 was localized inside reticulocytes. However, in cells incubated for an additional 24 h with CASIN, Cdc42 was not localized near the nucleus, and F-actin did not accumulate (Fig. 5B).

In mouse erythroblasts, mDia2 plays a significant role in enucleation by influencing the formation of the contractile actomyosin ring. We also examined the localization of mDia2 in CFU-Es or erythroblasts. In day 8 cells, mDia2 was localized in the cytoplasm near the cell membrane in dividing cells and in the nucleus of interphase cells (Fig. 6A). Among cells incubated for an additional 24 h with CASIN, the number of mitotic phase cells was
small, and mDia2 was also localized in the nucleus (Fig. 6A). In day 11 cells, mDia2 was localized in the nucleus regardless of the treatment with CASIN (Fig. 6B). These results suggest that Cdc42 is involved in the formation of the contractile actomyosin ring in erythroblasts, and that mDia2 as a downstream effector of Cdc42 is associated with the proliferation of erythroblasts, while mDia2 does not appear to be associated with enucleation.

**Discussion**

In the present study, we investigated the expression and localization of Cdc42 in human erythroblasts during terminal differentiation. Furthermore, the inhibition of Cdc42 activity by CASIN blocked the proliferation and differentiation of CFU-Es and enucleation of erythroblasts. A key result was that the inhibition of Cdc42 blocked both the cell polarization and formation of contractile rings in human erythroblasts during terminal differentiation. These results suggest that Cdc42 signaling transduction is constantly used for the maturation process of human erythroblasts.

A previous study by Yang et al. demonstrated that a Cdc42 deficiency caused anemia and splenomegaly accompanied by decreased burst-forming units-erythroid (BFU-Es) and CFU-Es in mice26. Their findings...
indicated that a Cdc42 deficiency causes a block in the early stage of erythropoiesis in mice. The present results suggested that the inhibition of Cdc42 blocked both the proliferation and differentiation of CFU-Es. In contrast, to the best of our knowledge, the functional roles of Cdc42 in the late stage of erythropoiesis currently remain unknown. Our results showed that the inhibition of Cdc42 impaired both the polarization and extrusion of the nucleus in the late stage of human erythroblasts, suggesting that Cdc42 acts on both the dynein–tubulin system and actin–myosin system in human erythroblasts.

In the present study, we examined the effects of the inhibition of Cdc42 on the localization of dynein in human erythroblasts. Tuncay et al. reported that junctional adhesion molecule-A (JAM-A) regulated dynein localization mediated by Cdc42 to control planar spindle orientation during mitosis in epithelial cells. Their findings showed that JAM-A triggered the transient activation of Cdc42 and PI3K, generated a gradient of PtdIns(3,4,5)P3 at the cortex, and regulated the formation of the cortical actin cytoskeleton during mitosis. When the JAM-A was inhibited by siRNA, dynactin that forms a complex with dynein localization at the cortex is reduced, the mitotic spindle apparatus is misaligned, and epithelial morphogenesis in a three-dimensional culture is compromised.

The present results showed that the localization of dynein was changed from an island-like distribution in the cytoplasm to near the nucleus in a dot pattern and was co-localized with γ-tubulin by the inhibition of Cdc42 in human CFU-Es and erythroblasts. These results are consistent with the localization of dynactin at the cortex being reduced and only being near MTOCs in JAM-A knockdown cells. Collectively, these findings and the present results imply that signaling through Cdc42 stops the motion of the dynein–dynactin complex, and, thus, further studies are required.

To the best of our knowledge, the localization of Cdc42 during human erythropoiesis has not yet been examined. This is the first study to characterize the localization of Cdc42 in human erythroblasts. We confirmed that
Figure 4. Effects of the inhibition of Cdc42 by CASIN on the ratio of cell polarization. Day 10 erythroblasts (1 × 10⁵) were cultured with or without CASIN, and were harvested 24 h after the addition of CASIN. "Centered", "Polarized", "Others", and "Reticulocytes" were explained in "Methods". Data are shown as the means ± SD of 3 independent experiments (N = 300). DMSO vs. 25 µM CASIN, *P < 0.05 and **P < 0.01.

Figure 5. Distribution of Cdc42 and F-actin in CFU-Es and erythroblasts with or without the CASIN treatment. Confocal microscopy of (A) CFU-Es (day 8 cells) and (B) erythroblasts (day 11 cells) stained by Cdc42 (red), phalloidin (green), and DAPI (blue), and differential interference contrast microscopic images (DIC) are shown. These are entire confocal stacks. DMSO and 25 µM CASIN denote day 7 or day 10 cells, respectively, treated for 24 h without and with 25 µM CASIN. Bar 20 µm.
Cdc42 was localized at the position at which the accumulation of F-actin occurred in CFU-Es and erythroblasts. In somatic cells, the localization and activity of Cdc42 during cytokinesis has not yet been examined in detail in animal cells\(^2\). Previous studies reported that RhoA, which is similar to Cdc42, was important for forming contractile actomyosin rings; however, these findings are controversial\(^2\). The present results imply that Cdc42 plays an important role in the formation of contractile actomyosin rings in CFU-Es and erythroblasts.

We showed that during the cell division of CFU-Es, the localization of mDia2 changed from the nucleus to the cytoplasmic membrane. This result is in agreement with previous findings obtained using human and mouse cells\(^2\). Moreover, we found that the localization of mDia2 remained unchanged in the nucleus during the enucleation of erythroblasts. Ji et al. demonstrated that the percentage of enucleated erythroblasts in mDia2 shRNA-treated cells in mice decreased, and suggested the involvement of mDia2 in enucleation\(^7\). On the other hand, Watanabe et al. demonstrated that mDia2-deficient mouse erythroid cells differentiated normally, albeit in a delayed manner, but exhibited failed cytokinesis with the decreased accumulation of F-actin in the cleavage furrow during late differentiation from proerythroblasts\(^20\). mDia2-deficient mouse erythroblasts enucleate their nuclei. These findings suggest blocked enucleation by the inhibition of mDia2 in mouse erythroid cells due to failed cytokinesis during erythroid differentiation. The present results appear to support Watanabe's findings. Additionally, the inhibition of Cdc42 changed the localization of mDia2 in CFU-Es during cell division, but not the enucleation of erythroblasts. These results suggest that mDia2 as a downstream molecule of Cdc42 was involved in at least the proliferation of CFU-Es, but not in the enucleation of erythroblasts. To confirm this, further information on whether mDia2 is essential for the enucleation of human erythroblasts is needed. It is important for us to establish a gene transfer technique in human erythroblasts.

Pathologically, an abnormality in Cdc42 causes a clinically heterogeneous group of phenotypes characterized by variable growth dysregulation, facial dysmorphism, and neurodevelopmental, immunological, and hematological anomalies\(^31\). A previous study reported that hematological anomalies include lymphatic and platelet anomalies\(^33\). However, to the best of our knowledge, erythrocytic anomalies, such as anemia, attributed to Cdc42 abnormalities have not yet been reported. In mice, a Cdc42 deficiency is a fatal symptom with anemia\(^26\), and this may also be the case in humans.
In conclusion, we herein demonstrated that Cdc42 is important in human erythropoiesis. Furthermore, the present results indicate that Cdc42 plays an important role in both nuclear polarization and nuclear extrusion through the control of dynein and actin filament organization during the terminal differentiation of human erythroblasts.

Methods
Reagents and inhibitors. Bovine serum albumin (BSA), Iscove’s Modified Dulbecco’s Medium (IMDM), and propidium iodide (PI) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal calf serum (FCS) was from HyClone Laboratories Inc. (Logan, UT). Penicillin and streptomycin were from Flow Laboratories. Insulin was from Wako Pure Chemical Industries (Osaka, Japan). Interleukin-3 (IL-3) and stem cell factor (SCF) were from Kirin Brewery Co., Ltd. (Tokyo, Japan). Erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) were from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Vitamin B12 was from Eisai Co., Ltd. (Tokyo, Japan), and folic acid was from Takeda Pharmaceutical Co., Ltd. (Osaka, Japan). Triton X-100 was from Wako Pure Chemical Industries (Osaka, Japan). MACS MicroBeads for indirect magnetic labeling were from Miltenyi Biotec (Bergisch-Gladbach, Germany). Normal mouse and goat sera as well as rabbit immunoglobulins were from Cell Signaling Technology (Beverly, MA, USA). CASIN, 2-[(2,3,4,9-Tetrahydro-6-phenyl-1H-carbazol-1-yl] and the antibodies used in the present study are listed in Table 1.

Cell preparations. G-CSF-mobilized human peripheral blood CD34+ cells were purified from healthy volunteers as described previously and stored in liquid nitrogen until required[1]. Informed consent was obtained from all subjects prior to their entry into the present study, which was pre-approved by the Akita University Graduate School of Medicine Committee for the Protection of Human Subjects, according to the Declaration of Helsinki[2]. To generate erythroid progenitor cells, CD34+ cells were thawed out and prepared for culture as previously described[1,3]. Cells were cultured in IMDM erythroid medium containing 20% FCS, 10% heat-inactivated pooled human AB serum, 1% BSA, 10 μg/ml insulin, 0.5 μg/ml vitamin B12, 15 μg/ml folic acid, 50 nM β-mercaptoethanol, 50 U/ml penicillin, and 50 μg/ml streptomycin and supplemented with 50 ng/ml IL-3, 50 ng/ml SCF, and 2 IU/ml EPO. Cells were maintained in an incubator at 37 °C and 5% CO2. On day
7 of the culture (day 7), cells were harvested and washed three times with IMDM containing 0.3% BSA and stored at 4 °C until further use. The maturation stage of day 7 cells was similar to that of CFU-Es, as reported previously. Day 7 cells were hereafter referred to as CFU-Es. Aliquots of CFU-Es were cultured in erythroid medium with EPO alone without β-ME, SCF, or IL-3 to induce differentiation and supplemented with or without CASIN. DMSO, a solvent of CASIN, was used as a control. The final concentration of DMSO was 0.025%, which was markedly lower than the concentration that is toxic to human erythroblasts. Cells were harvested at various time points, washed three times with IMDM containing 0.3% BSA, resuspended in IMDM containing 0.3% BSA, and stored at 4 °C until further use.

To evaluate enucleation, cells were spun down onto slides using Cytospin 3 (Shandon Lipshaw Inc., Pittsburgh, PA, USA) and stained with May–Grünwald–Giemsa. Enucleation was defined as the expulsion of the nucleus to the outside of the reticulocyte. Reticulocytes still in contact with expelled nuclei or with a thin connecting strand between the reticulocyte and nucleus were regarded as the latest enucleated cells. The enucleation fraction was calculated using the formula [erythrocytes/(erythrocytes + erythroblasts)] × 100 (%) after counting 300 cells, including erythrocytes and erythroblasts, in each slide. Triplicate cultures were used at each time point. Yield and viability were assessed based on dye exclusion using 0.2% trypan blue.

**Table 1.** Antibodies used in immunoblot analyses or immunocytochemical staining. *The amino acid sequences of all antigens were derived from human resources. Poly or mono indicates a polyclonal or monoclonal antibody, respectively.*

| Antigena | Host animal/polyclonal or monoclonalb | Vendor information |
|----------|--------------------------------------|--------------------|
| α-Tubulin | Mouse/mono                           | Sigma-Aldrich-T9026 |
| γ-Tubulin | Mouse/mono                           | Abcam-ab11316       |
| Cdc42    | Rabbit/poly                          | Millipore-07–1,466  |
| Cdc42    | Mouse/mono                           | Santa Cruz-sc-8401  |
| Dynemin  | Rabbit/mono                          | Abcam-ab157468      |
| mDia2    | Mouse/mono                           | Santa Cruz-sc-293288|
| Alexa Fluor 488 mouse IgG | Goat/poly | Thermo Fisher-A-11001 |
| Alexa Fluor 488 rabbit IgG | Goat/poly | Thermo Fisher-A-11008 |
| Alexa Fluor 546 mouse IgG | Goat/poly | Thermo Fisher-A-11003 |
| Alexa Fluor 546 rabbit IgG | Goat/poly | Thermo Fisher-A-11010 |
| HRP-linked mouse IgG | Goat/poly | KPL-074-1809 |
| HRP-linked rabbit IgG | Goat/poly | Cell Signaling-7074 |

**Real-time PCR analysis.** Real-time PCR was performed as previously described. Briefly, total RNA was extracted from 2 × 10⁵ cultured cells per sample using the RNeasy Mini Kit (QIAGEN, Hilden, Germany). Extracted RNA was reverse-transcribed using the PrimeScript 1st strand cDNA Synthesis Kit (TAKaRA Bio Inc., Shiga, Japan). The resultant cDNA was then subjected to real-time PCR using LightCycler 480 SYBR Green I Master (Roche Applied Science, Mannheim, Germany). PCR primer sequences: CDC42 forward primer 5′-CTG TCAAGTATGTGGAGTGTTCTG-3′ and reverse primer 5′-CTCCTTTCTGCTTCTGGAGGCT-3′; 28S rRNA forward primer 5′-TGGTTTATAGCAGGAGGTG-3′ and reverse primer 5′-CCAGCTCAGTTCCTATTAT-3′. Relative gene expression levels were normalized with the 28S rRNA gene as previously described. Each sample was amplified in triplicate.

**Immunoblot analysis.** An immunoblot analysis was performed as previously described. The primary and secondary antibodies used in the present study are listed in Table 1. ECL Select Western Blotting Detection Reagent (GE Healthcare, Buckinghamshire, UK) was used for color development. The intensities of immunoreactive protein bands were quantified using c-DiGit (LI-COR, Nebraska, USA). The relative expression levels of the proteins analyzed were normalized with α-tubulin expression.

**Flow cytometry.** Flow cytometry was performed as previously described. Briefly, cells collected from cultures were washed twice with IMDM containing 0.3% BSA, and incubated with a phycoerythrin-conjugated mouse monoclonal antibody to human CD71 (transferrin receptor) (BD Biosciences, Franklin Lakes, NJ, USA) and fluorescein isothiocyanate-conjugated mouse monoclonal antibody to human GPA (Dako, Santa Clara, CA, USA). Cells were then washed twice with 10 mM sodium phosphate buffer, pH 7.4 and 0.15 M NaCl (phosphate-buffered saline: PBS) containing 0.5% BSA, and then analyzed using FACSCanto II (BD Biosciences) and FlowJo (BD Biosciences). Cell cycle distribution was performed as previously described.

**Morphological and immunocytochemical analyses of cells cultured with and without inhibitors.** Cells were classified based on whether the nucleus was localized at the center of cells (centered); spherical cells contained a condensed nucleus located to one side, near the plasma membrane (polarized), or were enucleated (reticulocytes). Other cell types, such as multinucleate cells and cells with condensed apoptotic nuclei,
were classified as "others". Images of cells were classified as previously described. The fractions of each cell type were calculated as described above. Results are presented as the mean of 3 independent experiments, mean ± SD.

**Confocal microscopy.** The immunocytochemical distributions of Cdc42, F-actin, dynein, γ-tubulin, α-tubulin, and mDia2 were assessed using confocal microscopy, as described above. Day 7 or day 10 cells were cultured in the presence or absence of 25 µM CASIN.

Conventional immunocytochemical staining was performed as described previously. Fluorescent staining was imaged using two confocal laser scanning microscopes (LSM780, Carl Zeiss Microscope Systems, Germany) equipped with 100× objective lenses and 10× camera lenses (Carl Zeiss Microscope Systems) at zoom 3, as reported elsewhere. Fluorochromes were excited using an argon laser at 488 nm for Alexa 488. Detector slits were configured to minimize cross talk between channels and processes using ZEN2012 Ver 3.2 (ZEISS).

**Statistical analysis.** Statistical analyses were performed using the Student's t test for parametric data and the Mann–Whitney U test for non-parametric data. P values <0.05 were considered to be significant in all analyses.

Received: 30 January 2020; Accepted: 2 July 2020
Published online: 16 July 2020

**References**

1. Kobayashi, I. et al. Erythroblast enucleation is a dynein-dependent process. *Exp. Hematol.* **44**, 247–256 (2016).
2. Ubukawa, K. et al. Enucleation of human erythroblasts involves non-muscle myosin IIIB. *Blood* **119**, 1036–1044 (2012).
3. Koury, S. T., Koury, M. J. & Bondurant, M. C. Cytoskeletal distribution and function during the maturation and enucleation of mammalian erythroblasts. *J. Cell Biol.* **109**, 3005–3013 (1989).
4. Glotzer, M. The molecular requirements for cytokinesis. *Science* **307**, 1735–1739 (2005).
5. Barr, F. A. & Gruneberg, U. Cytokinesis: Placing and making the final cut. *J. Cell Biol.* **173**, 847–860 (2006).
6. Wang, J. et al. Mammalian erythroblast enucleation requires PI3K-dependent cell polarization. *J. Cell Sci.* **125**, 340–349 (2012).
7. Li, P., Jayapal, S. R. & Lodish, H. F. Enucleation of cultured mouse fetal erythroblasts requires Rac GTPases and mDia2. *Nat. Cell Biol.* **10**, 314–321 (2008).
8. Nowak, R. B. et al. Tropomodulin 1 controls erythroblast enucleation via regulation of F-actin in the enucleosome. *Blood* **130**, 1144–1155 (2017).
9. Wolwer, C. B., Pase, L. B., Russell, S. M. & Humbert, P. O. Calcium signaling is required for erythroid enucleation. *PLoS One* **11**, e0146201. https://doi.org/10.1371/journal.pone.0146201 (2016).
10. Wolwer, C. B. et al. The asymmetric cell division regulators Par3, Scribble and Pins/Gspm2 are not essential for erythroid development or enucleation. *PLoS One* **12**, e0170295. https://doi.org/10.1371/journal.pone.0170295 (2017).
11. Wolwer, C. B. et al. A chemical screening approach to identify novel key mediators of erythroid enucleation. *PLoS One* **10**, e0142655. https://doi.org/10.1371/journal.pone.0142655 (2015).
12. Etienne-Manneville, S. & Hall, A. RhoGTPases in cell biology. *Nature* **420**, 629–635 (2002).
13. Geiger, H. & Zheng, Y. Regulation of hematopoietic stem cell aging by the small RhoGTPase Cdc42. *Exp. Cell Res.* **329**, 214–219 (2014).
14. Bishop, A. L. & Hall, A. Rho GT- Pases and their effector proteins. *Biochem. J.* **348**, 241–255 (2000).
15. Kesavan, G. et al. Cdc42-mediated tubulogenesis controls cell specification. *Cell* **139**, 791–801 (2009).
16. Toyoshima, F., Matsumura, S., Morimoto, H., Mitsushima, M. & Nishida, E. Phosphorylation of linker region regulates dynein orientation in adherent cells. *Dev. Cell* **13**, 796–811 (2007).
17. Mitsushima, M., Toyoshima, F. & Nishida, E. Dual role of Cdc42 in spindle orientation control of adherent cells. *Mol. Cell Biol.* **29**, 2816–2827 (2009).
18. Heasman, S. J. & Ridley, A. J. Mammalian Rho GTPases: New insights into their functions from in vivo studies. *Nat. Rev. Mol. Cell Biol.* **9**, 690–701 (2008).
19. Watanabe, S. et al. mDia2 induces the actin scaffold for the contractile ring and stabilizes its position during cytokinesis in NIH 3T3 cells. *Mol. Biol. Cell* **19**, 2328–2338 (2008).
20. Watanabe, S. et al. Loss of a Rho-regulated actin nucleator, mDia2, impairs cytokinesis during mouse fetal erythropoiesis. *Cell Rep.* **5**, 926–932 (2013).
21. Goto, T. et al. ATP produced by anaerobic glycolysis is essential for enucleation of human erythroblasts. *Exp. Hematol.* **72**, 14–26 (2019).
22. Florian, M. C. et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. *Cell Stem Cell* **10**, 520–530 (2012).
23. Araki, K. et al. The localization of α-synuclein in the process of differentiation of human erythroid cells. *Int. J. Hematol.* **108**, 130–138 (2018).
24. Pan, D. et al. K-CI cotransporter gene expression during human and murine erythrocyte differentiation. *J. Biol. Chem.* **286**, 30492–30503 (2011).
25. Migliazzo, A. R., Masselli, E., Varricchio, L. & Whitsett, C. Ex vivo expansion of red blood cells: How real for transfusion in humans? *Blood Rev.* **26**, 81–95 (2012).
26. Yang, L. et al. Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis. *Blood* **110**, 3853–3861 (2007).
27. Tuncay, H. et al. JAM-A regulates cortical dynein localization through Cdc42 to control planar spindle orientation during mitosis. *Nat. Commun.* **6**, 8128 (2015).
28. Jordan, S. N. & Canman, J. C. Rho GTPases in animal cell cytokinesis: An occupation by the one percent. *Cytoskeleton (Hoboken)*, **69**, 919–930 (2010).
29. Sankaran, J. S. et al. Knockdown of formin mDia2 alters lamin B1 levels and increases osteogenesis in stem cells. *Stem Cells* **20**, 1–16 (2019).
30. Watanabe, S. et al. Rho and anillin-dependent control of mDia2 localization and function in cytokinesis. *Mol. Biol. Cell* **21**, 3193–3204 (2010).
31. Martinelli, S. et al. Functional dysregulation of CDC42 causes diverse developmental phenotypes. *Am. J. Hum. Genet.* **102**, 309–320 (2018).
32. Oda, A. et al. Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT3B in primary cultured human erythroid precursors. *Blood* **92**, 443–451 (1998).
33. Hebiguchi, M. et al. Dynamics of human erythroblast enucleation. *Int. J. Hematol.* **88**, 498–507 (2008).
34. Guo, Y. M. et al. CpG-ODN 2006 and human parvovirus B19 genome consensus sequences selectively inhibit growth and development of erythroid progenitor cells. *Blood* **115**, 4569–4579 (2010).

**Acknowledgements**
This work was supported in part by JSPS KAKENHI Grant No. 18K08305 (KU). This work was also supported in part by a private donation from Dr. Ken Satoh, Satoh Naika Clinic, Sakata, Japan. The authors are grateful to Ms. Hiromi Kataho, Ms. Yukiko Abe, and Ms. Yuko Chiba Akita University, for their valuable technical assistance with cell staining.

**Author contributions**
K.U. designed the study, designed and performed experiments, analyzed data, and wrote the manuscript; T.G. designed and performed experiments, analyzed data, and wrote the manuscript; K.A., Y.S., Y.-M.G. and I.K. performed experiments and contributed to data analysis; and K.S., H.W. and N.T. interpreted the data and contributed to writing the manuscript. All authors read and approved the final manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-68799-1.

**Correspondence** and requests for materials should be addressed to K.U.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020